CD274 and non-small cell lung carcinoma: Among them, PD-L1 expression, TMB (≥ 10 mut/Mb), microsatellite instability (MSI-H) and mismatch repair deficient (MMR) have been approved by health regulatory agencies, which can serve as predictive biomarkers for immunotherapy of NSCLC patients (Hellmann et al. 2018a, b; Marabelle et al. 2020; Bodor et al. 2020; Rizvi et al. 2018).